Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

A tumor suppressor of CLL: all (T-)bets are on

Paul Moss

Blood (2024) 144 (5): 467–469.

https://doi.org/10.1182/blood.2024025015

Published: 2024

Journal Articles

Ibrutinib reversal of immune exhaustion in CLL

Paul Moss

Blood (2024) 143 (1): 5–7.

https://doi.org/10.1182/blood.2023022243

Published: 2024

Journal Articles

The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial

Blood (2023) 142 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2023-188725

Published: 2023

Journal Articles

Serum Protein Markers of Survival, Relapse and GvHD Identified within the First Two Weeks Post Stem Cell Transplantation

Kriti Verma, Wayne Croft, David Greenwood, Christine Stephens, Francesca A Kinsella, Paul Moss

Blood (2022) 140 (Supplement 1): 12666.

https://doi.org/10.1182/blood-2022-170034

Published: 2022

Journal Articles

Blocking T Cell Co-Stimulation Via CD70 As a Target for Gvhd in Allogeneic Stem Cell Transplantation (SCT)

Kriti Verma, Jianmin Zuo, Christine Stephens, Francesca A Kinsella, Ram Malladi, Paul Moss

Blood (2022) 140 (Supplement 1): 12665.

https://doi.org/10.1182/blood-2022-169601

Published: 2022

Journal Articles

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah V. Giles, Mark A. Cook, Mark Trehane Drayson, Gordon Cook, Nicola Jane Wright, Simon John North, Stephen Harding, David A. Cairns, Anna Hockaday, Martin F. Kaiser, Paul Moss, Faith E. Davies, Gareth J. Morgan, Graham Jackson, Guy Pratt

Blood (2022) 139 (6): 946–950.

https://doi.org/10.1182/blood.2021013794

Published: 2022

Includes: Supplemental data

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

Low Numbers of CD27 - IgD - 'Double Negative' Senescent B-Cells Early after Reduced Intensity T Cell Depleted Haematopoietic Stem Cell Transplantation Are Predictive of Subsequent Chronic GvHD

Francesca Kinsella, PhD MRCP, FRCPath, Harriet Protheroe, MBChB BSc, Hayden Pearce, BSc. (Hons.), PhD, Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Joanne Croudace, PhD, Ben E Abbotts, BSc. (Hons.), MSc., Jianmin Zuo, PhD, Ram K Malladi, FRCPath, Charles Craddock, FRCP, FRCPath, Paul Moss, MBBS, PhD FRCP

Blood (2019) 134 (Supplement_1): 4529.

https://doi.org/10.1182/blood-2019-131130

Published: 2019

Journal Articles

The Proportion of CD52/GPI Negative T Cells Early Following Alemtuzumab Conditioned Haematopoetic Stem Cell Transplantation Is an Independent Risk Factor for Acute GvHD

Francesca Kinsella, PhD MRCP, FRCPath, Charlotte F Inman, BVSc, PhD, Duncan Murray, FRCPath, MRCP, MA, BMBS, Wayne Croft, PhD, Jianmin Zuo, PhD, Hayden Pearce, BSc. (Hons.), PhD, Sara Barbieri, BSc MSc, Jane Nunnick, BSC. (Hons.), MSc., Sandeep Nagra, MBChB, Charles Craddock, FRCP, FRCPath, Ram K Malladi, FRCPath, Paul Moss, MBBS, PhD FRCP

Blood (2019) 134 (Supplement_1): 4543.

https://doi.org/10.1182/blood-2019-128292

Published: 2019

Journal Articles

Targeting an RNaseH2 Defect in Chronic Lymphocytic Leukaemia with PARP Inhibitors

Angelo Agathaggelou, Olga Murina, Andrew P Jackson, Paul Moss, MBBS, PhD FRCP, Shankara Paneesha, MD, Grant S Stewart, Malcolm Taylor, PhD, Tatjana Stankovic, MD PhD

Blood (2018) 132 (Supplement 1): 1835.

https://doi.org/10.1182/blood-2018-99-115967

Published: 2018

Journal Articles

T Cell Versus T Cell; A Study of the Immune Checkpoint Landscape in Cutaneous T Cell Lymphoma

Duncan Murray, FRCPath, MRCP, MA, BMBS, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Nathaniel Davies, MSci, PhD, Jack McMurray, BSc, Julia J. Scarisbrick, MD FRCP, MBBS †, Paul Moss, MBBS, PhD FRCP

Blood (2017) 130 (Supplement 1): 2754.

https://doi.org/10.1182/blood.V130.Suppl_1.2754.2754

Published: 2017

Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3004.

https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004

Published: 2017

Journal Articles

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Ben E Abbotts, BSc. (Hons.), MSc., Mirjana Sirovica, BSc(Hons), MSc, Paul Ferguson, MD PhD MRCP, Donna L Walsh, Dip(HE), BSc., Jane Nunnick, BSC. (Hons.), MSc., Shamyla Siddique, BSc.(Hons.), MPhil, Paul Moss, MBBS, PhD FRCP, Ram K Malladi, FRCPath

Blood (2017) 130 (Supplement 1): 1908.

https://doi.org/10.1182/blood.V130.Suppl_1.1908.1908

Published: 2017

Journal Articles

NK Cells Produce High Levels of IL-10 Early after Allogeneic Stem Cell Transplantation and Suppress Development of Acute GVHD

Paul Moss, MBBS, PhD FRCP, Ram Malladi, MRCP, FRCPath, PhD, Tracey Chan, PhD, Jianmin Zuo, PhD

Blood (2017) 130 (Supplement 1): 5489.

https://doi.org/10.1182/blood.V130.Suppl_1.5489.5489

Published: 2017

Journal Articles

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status

Blood (2017) 130 (2): 156–166.

https://doi.org/10.1182/blood-2016-12-758219

Published: 2017

Includes: Supplemental data

Journal Articles

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 - or ATM -defective chronic lymphocytic leukemia cells

Marwan Kwok, Nicholas Davies, Angelo Agathanggelou, Edward Smith, Ceri Oldreive, Eva Petermann, Grant Stewart, Jeff Brown, Alan Lau, Guy Pratt, Helen Parry, Malcolm Taylor, Paul Moss, Peter Hillmen, Tatjana Stankovic

Blood (2016) 127 (5): 582–595.

https://doi.org/10.1182/blood-2015-05-644872

Published: 2016

Includes: Supplemental data

Journal Articles

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells

Laurie Menger, Agnes Gouble, Maria A. V. Marzolini, Annette Pachnio, Katharina Bergerhoff, Jake Y. Henry, Julianne Smith, Martin Pule, Paul Moss, Stanley R. Riddell, Sergio A. Quezada, Karl S. Peggs

Blood (2015) 126 (26): 2781–2789.

https://doi.org/10.1182/blood-2015-08-664755

Published: 2015

Includes: Supplemental data

Journal Articles

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event

David M. Burns, Rose Tierney, Claire Shannon-Lowe, Jo Croudace, Charlotte Inman, Ben Abbotts, Sandeep Nagra, Christopher P. Fox, Sridhar Chaganti, Charles F. Craddock, Paul Moss, Alan B. Rickinson, Martin Rowe, Andrew I. Bell

Blood (2015) 126 (25): 2665–2675.

https://doi.org/10.1182/blood-2015-08-665000

Published: 2015

Includes: Supplemental data

Journal Articles

UCHL1 Is a New Therapeutic Target in Lymphoid Malignancies, Independent of ATM and TP53 status

Edward Smith, MSc, Angelo Agathanggelou, PhD, Guy Pratt, MDPhD, Paul Moss, Wenbin Wei, PhD, Leanine Harrigan, Xavier Jacq, PhD, Tatjana Stankovic

Blood (2015) 126 (23): 1746.

https://doi.org/10.1182/blood.V126.23.1746.1746

Published: 2015

NARROW

A tumor suppressor of CLL: all (T-)bets are on

Ibrutinib reversal of immune exhaustion in CLL

The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial

Serum Protein Markers of Survival, Relapse and GvHD Identified within the First Two Weeks Post Stem Cell Transplantation

Blocking T Cell Co-Stimulation Via CD70 As a Target for Gvhd in Allogeneic Stem Cell Transplantation (SCT)

Redefining nonmeasurable multiple myeloma using mass spectrometry

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Low Numbers of CD27 - IgD - 'Double Negative' Senescent B-Cells Early after Reduced Intensity T Cell Depleted Haematopoietic Stem Cell Transplantation Are Predictive of Subsequent Chronic GvHD

The Proportion of CD52/GPI Negative T Cells Early Following Alemtuzumab Conditioned Haematopoetic Stem Cell Transplantation Is an Independent Risk Factor for Acute GvHD

Targeting an RNaseH2 Defect in Chronic Lymphocytic Leukaemia with PARP Inhibitors

T Cell Versus T Cell; A Study of the Immune Checkpoint Landscape in Cutaneous T Cell Lymphoma

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

NK Cells Produce High Levels of IL-10 Early after Allogeneic Stem Cell Transplantation and Suppress Development of Acute GVHD

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 - or ATM -defective chronic lymphocytic leukemia cells

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event

UCHL1 Is a New Therapeutic Target in Lymphoid Malignancies, Independent of ATM and TP53 status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only